fashion -WSS

fashion

author：hotspot 2025-10-02 00:40:59 - browse：45

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How Long Island became the ‘eugenics capital of the world’

knowledge

leisure time

WSS

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Study finds new variant for Parkinson’s in African populations

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Trial using CRISPR to edit HIV out of cells disappoints

Drug firms test therapies to halt Alzheimer’s before symptoms arise

As pharma fights Medicare drug negotiation, hospitals, docs silent

Wikipedia

fashion

focus

In Memoriam: Notable people who died in 2023

UnitedHealth, in a surprise, takes aim at Steward’s physician group

As demand for Covid shots wanes, Moderna seeks its next success

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Dobbs anniversary: the lost opportunity of abortion as health care

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Anesthesiologist group: stop taking Ozempic before surgery

How Long Island became the ‘eugenics capital of the world’

As demand for Covid shots wanes, Moderna seeks its next success

AstraZeneca challenges Medicare drug negotiation program

leisure time

Medicare explains how it will choose drugs for negotiation

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

In science, is the line between industry and academia shifting?

Study finds new variant for Parkinson’s in African populations

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

What do new weight loss drugs mean for bariatric surgery?

focus

knowledge

leisure time

leisure time